Akari Therapeutics, Plc (AKTX) News
Track canonical SquawkNews coverage tagged to AKTX, Akari Therapeutics, Plc. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Amazon.com Inc (NASDAQ: AMZN ) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the
EARNINGS | Jul 31, 2026, 08:50 AM UTC
L
AKTX Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics Akari Therapeutics - Co and Whitehawk to conduct
AKTX Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics Akari Therapeutics - Co and Whitehawk to conduct preclinical studies of ph1 payload with top1i Adc platform - Collaboration to c
EQUITY | Jul 21, 2026, 11:31 AM UTC
L
moves among today's upgrades NBIS +7.3%, LITE +6.0%, AKTX +5.7%, URBN +3.1%, YETI +2.2%, HOG +1.8%, GPN +1.5%, USB +0.6%, NFLX -1.8% moves a
moves among today's upgrades NBIS +7.3%, LITE +6.0%, AKTX +5.7%, URBN +3.1%, YETI +2.2%, HOG +1.8%, GPN +1.5%, USB +0.6%, NFLX -1.8% moves among today's positive initiations NNBR +8.0%, RNTX +3.2%, SLNH +15.5%, ANTX +9.6
EQUITY | Jul 20, 2026, 01:42 PM UTC
L
AKTX Upgrade from Hold to Buy W/$30.00 PT at Maxim Group
AKTX Upgrade from Hold to Buy W/$30.00 PT at Maxim Group
EQUITY | Jul 20, 2026, 11:49 AM UTC
L
Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders
SEC Filing
REGULATION | Jul 02, 2026, 09:30 PM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC